INTECH Investment Management’s Esperion Therapeutics ESPR Stock Holding History

INTECH Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$181K	Sell	57,200 -5,420	-9%	-$15.2K	﹤0.01%	1818
2026 Q1	$172K	Sell	62,620 -42,318	-40%	-$134K	﹤0.01%	1793
2025 Q4	$388K	Buy	104,938 +5,447	+5%	+$17.6K	﹤0.01%	1628
2025 Q3	$264K	Sell	99,491 -23,549	-19%	-$45.5K	﹤0.01%	1906
2025 Q2	$121K	Buy	123,040 +28,695	+30%	+$28.7K	﹤0.01%	2244
2025 Q1	$136K	Buy	94,345 +12,960	+16%	+$23.9K	﹤0.01%	2224
2024 Q4	$179K	Buy	81,385 +24,481	+43%	+$57.1K	﹤0.01%	2068
2024 Q3	$93.9K	Buy	+56,904	New	+$115K	﹤0.01%	1894

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

INTECH Investment Management's ESPR Position: Q2 2026 in Review

INTECH Investment Management reduced its Esperion Therapeutics (ESPR) stake by 8.7% in Q2 2026, selling an estimated $15.2K and leaving 57,200 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #1818.

INTECH Investment Management first reported a position in ESPR in Q3 2024 and has held it in 8 quarters since. The position peaked at $388K in Q4 2025. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

INTECH Investment Management held 57,200 shares of Esperion Therapeutics worth $181K as of Q2 2026.
INTECH Investment Management sold 5,420 Esperion Therapeutics shares in Q2 2026, an estimated $15.2K.
Esperion Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1818 holding.
INTECH Investment Management first reported a position in Esperion Therapeutics in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Esperion Therapeutics position peaked at $388K in Q4 2025.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.